Alfresa Holdings Corporation
Alfresa Holdings Corporation ARHCF Peers
See (ARHCF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARHCF | $11.87 | N/A | 2.2B | 9.97 | $1.19 | +0.03% |
| SHPMF | $1.57 | +0.51% | 8.7B | 9.81 | $0.16 | +4.31% |
| SHTDF | $2.50 | +14.68% | 7.8B | 8.06 | $0.31 | +3.75% |
| SHTDY | $11.58 | -0.43% | 7.2B | 7.38 | $1.57 | +4.07% |
| CAKFY | $4.10 | N/A | 5.4B | -68.33 | -$0.06 | N/A |
| AMFPF | $22.86 | -4.15% | 5.1B | 31.32 | $0.73 | +1.43% |
| MEPDF | $21.06 | +19.86% | 4.4B | 15.83 | $1.33 | +2.01% |
| GALNF | $75.25 | N/A | 3.7B | 20.23 | $3.72 | +3.71% |
| MAHLY | $16.05 | +7.36% | 3.3B | 11.98 | $1.34 | +1.72% |
| ALFRY | $15.99 | N/A | 2.9B | 15.68 | $1.02 | N/A |
Stock Comparison
ARHCF vs SHPMF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, SHPMF has a market cap of 8.7B. Regarding current trading prices, ARHCF is priced at $11.87, while SHPMF trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas SHPMF's P/E ratio is 9.81. In terms of profitability, ARHCF's ROE is +0.05%, compared to SHPMF's ROE of +0.06%. Regarding short-term risk, ARHCF and SHPMF have similar daily volatility (0.00).
ARHCF vs SHTDF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, SHTDF has a market cap of 7.8B. Regarding current trading prices, ARHCF is priced at $11.87, while SHTDF trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas SHTDF's P/E ratio is 8.06. In terms of profitability, ARHCF's ROE is +0.05%, compared to SHTDF's ROE of +0.06%. Regarding short-term risk, ARHCF and SHTDF have similar daily volatility (0.00).
ARHCF vs SHTDY Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, SHTDY has a market cap of 7.2B. Regarding current trading prices, ARHCF is priced at $11.87, while SHTDY trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas SHTDY's P/E ratio is 7.38. In terms of profitability, ARHCF's ROE is +0.05%, compared to SHTDY's ROE of +0.09%. Regarding short-term risk, ARHCF is less volatile compared to SHTDY. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs CAKFY Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, CAKFY has a market cap of 5.4B. Regarding current trading prices, ARHCF is priced at $11.87, while CAKFY trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas CAKFY's P/E ratio is -68.33. In terms of profitability, ARHCF's ROE is +0.05%, compared to CAKFY's ROE of -0.02%. Regarding short-term risk, ARHCF and CAKFY have similar daily volatility (0.00).
ARHCF vs AMFPF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, AMFPF has a market cap of 5.1B. Regarding current trading prices, ARHCF is priced at $11.87, while AMFPF trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas AMFPF's P/E ratio is 31.32. In terms of profitability, ARHCF's ROE is +0.05%, compared to AMFPF's ROE of +0.13%. Regarding short-term risk, ARHCF and AMFPF have similar daily volatility (0.00).
ARHCF vs MEPDF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, MEPDF has a market cap of 4.4B. Regarding current trading prices, ARHCF is priced at $11.87, while MEPDF trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas MEPDF's P/E ratio is 15.83. In terms of profitability, ARHCF's ROE is +0.05%, compared to MEPDF's ROE of +0.08%. Regarding short-term risk, ARHCF is less volatile compared to MEPDF. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs GALNF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, GALNF has a market cap of 3.7B. Regarding current trading prices, ARHCF is priced at $11.87, while GALNF trades at $75.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas GALNF's P/E ratio is 20.23. In terms of profitability, ARHCF's ROE is +0.05%, compared to GALNF's ROE of +0.12%. Regarding short-term risk, ARHCF and GALNF have similar daily volatility (0.00).
ARHCF vs MAHLY Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, MAHLY has a market cap of 3.3B. Regarding current trading prices, ARHCF is priced at $11.87, while MAHLY trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas MAHLY's P/E ratio is 11.98. In terms of profitability, ARHCF's ROE is +0.05%, compared to MAHLY's ROE of +0.06%. Regarding short-term risk, ARHCF and MAHLY have similar daily volatility (0.00).
ARHCF vs ALFRY Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, ALFRY has a market cap of 2.9B. Regarding current trading prices, ARHCF is priced at $11.87, while ALFRY trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas ALFRY's P/E ratio is 15.68. In terms of profitability, ARHCF's ROE is +0.05%, compared to ALFRY's ROE of +0.05%. Regarding short-term risk, ARHCF and ALFRY have similar daily volatility (0.00).
ARHCF vs SHPMY Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, SHPMY has a market cap of 1.8B. Regarding current trading prices, ARHCF is priced at $11.87, while SHPMY trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas SHPMY's P/E ratio is 8.75. In terms of profitability, ARHCF's ROE is +0.05%, compared to SHPMY's ROE of +0.06%. Regarding short-term risk, ARHCF is less volatile compared to SHPMY. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs SZUKF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, SZUKF has a market cap of 1.7B. Regarding current trading prices, ARHCF is priced at $11.87, while SZUKF trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas SZUKF's P/E ratio is 11.43. In terms of profitability, ARHCF's ROE is +0.05%, compared to SZUKF's ROE of +0.04%. Regarding short-term risk, ARHCF and SZUKF have similar daily volatility (0.00).
ARHCF vs MEDOF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, MEDOF has a market cap of 1.3B. Regarding current trading prices, ARHCF is priced at $11.87, while MEDOF trades at $50.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas MEDOF's P/E ratio is 73.53. In terms of profitability, ARHCF's ROE is +0.05%, compared to MEDOF's ROE of +0.03%. Regarding short-term risk, ARHCF is less volatile compared to MEDOF. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs ARRJF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, ARRJF has a market cap of 1.3B. Regarding current trading prices, ARHCF is priced at $11.87, while ARRJF trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas ARRJF's P/E ratio is 27.00. In terms of profitability, ARHCF's ROE is +0.05%, compared to ARRJF's ROE of +0.06%. Regarding short-term risk, ARHCF and ARRJF have similar daily volatility (0.00).
ARHCF vs IUSDF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, IUSDF has a market cap of 605.5M. Regarding current trading prices, ARHCF is priced at $11.87, while IUSDF trades at $23.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas IUSDF's P/E ratio is 30.05. In terms of profitability, ARHCF's ROE is +0.05%, compared to IUSDF's ROE of +0.12%. Regarding short-term risk, ARHCF is less volatile compared to IUSDF. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs EXHI Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, EXHI has a market cap of 15M. Regarding current trading prices, ARHCF is priced at $11.87, while EXHI trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas EXHI's P/E ratio is N/A. In terms of profitability, ARHCF's ROE is +0.05%, compared to EXHI's ROE of +0.00%. Regarding short-term risk, ARHCF and EXHI have similar daily volatility (0.00).
ARHCF vs ENMI Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, ENMI has a market cap of 13.4M. Regarding current trading prices, ARHCF is priced at $11.87, while ENMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas ENMI's P/E ratio is -0.35. In terms of profitability, ARHCF's ROE is +0.05%, compared to ENMI's ROE of +0.51%. Regarding short-term risk, ARHCF and ENMI have similar daily volatility (0.00).
ARHCF vs NSVGF Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, NSVGF has a market cap of 8.5M. Regarding current trading prices, ARHCF is priced at $11.87, while NSVGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas NSVGF's P/E ratio is -1.00. In terms of profitability, ARHCF's ROE is +0.05%, compared to NSVGF's ROE of +0.21%. Regarding short-term risk, ARHCF and NSVGF have similar daily volatility (0.00).
ARHCF vs KOSK Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, KOSK has a market cap of 4.3M. Regarding current trading prices, ARHCF is priced at $11.87, while KOSK trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas KOSK's P/E ratio is -0.22. In terms of profitability, ARHCF's ROE is +0.05%, compared to KOSK's ROE of -0.13%. Regarding short-term risk, ARHCF is less volatile compared to KOSK. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs PDRX Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, PDRX has a market cap of 3.9M. Regarding current trading prices, ARHCF is priced at $11.87, while PDRX trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas PDRX's P/E ratio is 2.31. In terms of profitability, ARHCF's ROE is +0.05%, compared to PDRX's ROE of -0.07%. Regarding short-term risk, ARHCF is less volatile compared to PDRX. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs ITNS Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, ITNS has a market cap of 609.4K. Regarding current trading prices, ARHCF is priced at $11.87, while ITNS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas ITNS's P/E ratio is -0.04. In terms of profitability, ARHCF's ROE is +0.05%, compared to ITNS's ROE of +0.01%. Regarding short-term risk, ARHCF is less volatile compared to ITNS. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs PHRX Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, PHRX has a market cap of 155.1K. Regarding current trading prices, ARHCF is priced at $11.87, while PHRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas PHRX's P/E ratio is N/A. In terms of profitability, ARHCF's ROE is +0.05%, compared to PHRX's ROE of +0.85%. Regarding short-term risk, ARHCF is less volatile compared to PHRX. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs CHME Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, CHME has a market cap of 7.1K. Regarding current trading prices, ARHCF is priced at $11.87, while CHME trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas CHME's P/E ratio is N/A. In terms of profitability, ARHCF's ROE is +0.05%, compared to CHME's ROE of +0.04%. Regarding short-term risk, ARHCF and CHME have similar daily volatility (0.00).
ARHCF vs MLTO Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, MLTO has a market cap of 1.7K. Regarding current trading prices, ARHCF is priced at $11.87, while MLTO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas MLTO's P/E ratio is -0.00. In terms of profitability, ARHCF's ROE is +0.05%, compared to MLTO's ROE of N/A. Regarding short-term risk, ARHCF is less volatile compared to MLTO. This indicates potentially lower risk in terms of short-term price fluctuations for ARHCF.
ARHCF vs TGVN Comparison
ARHCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARHCF stands at 2.2B. In comparison, TGVN has a market cap of 120. Regarding current trading prices, ARHCF is priced at $11.87, while TGVN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARHCF currently has a P/E ratio of 9.97, whereas TGVN's P/E ratio is -0.00. In terms of profitability, ARHCF's ROE is +0.05%, compared to TGVN's ROE of N/A. Regarding short-term risk, ARHCF and TGVN have similar daily volatility (0.00).